Enlivex Therapeutics Ltd (ENLV) Stock Price, Quote & News

Company Profile

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage kne...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 2 620 8072

Website: www.enlivex.com

Address:

14 Einstein Street, Ness Ziona, Israel

Burg44 Mar. 25 at 7:57 PM

$ENLV Crazy, they have $25 per share and only around $1? If this stock was rated as an average stock with a PE of 20x, that makes this $500 per share !!!

0 · Reply

Supera15 Mar. 25 at 5:38 PM

$ENLV didnt know a stock has to be a pos upon good news.

0 · Reply

trt102967 Mar. 25 at 4:31 PM

$ENLV

0 · Reply

PSM_EmpowerTrading Mar. 25 at 1:25 PM

🌅 Watchlist part 1 ✅ $RMSG low .50 support, if above .75, have potential to 1/1.30 ✅ $ITOC low .45 support, if above .55, have potential to .75/.85 ✅ $BZAI 1.50 support, if above 1.75, have potential to 2/2.20 ✅ $ENLV 1.20 support, if above 1.45, have potential to 1.70/1.75 ✅ $FEED 2.50 support, if above 2.80, have potential to 3/3.50 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D

0 · Reply

topstockalerts Mar. 25 at 1:17 PM

$ENLV waking up..

1 · Reply

MadMaverick Mar. 25 at 1:16 PM

⚡MORNING WATCHLIST⚡ $BZAI Entry above: $1.61 🎯 $1.71/$1.81 🛑 $1.53 $NXTT Entry above: $1.25 🎯 $1.40/$1.57 🛑 $1.17 $ENLV Entry above: $1.45 🎯 $1.55/$1.70 🛑 $1.38 $DXYZ Entry above: $33.30 🎯 $35/$37 🛑 $32 Note: These are trade ideas based on break-out levels, once they hit entry & start moving up, consider raising your stops to protect your profits and protect your downside according to your own trading plan :). MadMaverick personally trades these on either the 2 or 3 minute timeframes, waiting for a candle to close over the entry level. Although we do extensive research for our watchlist, day trading, especially with low-float stocks, can be risky.

0 · Reply

ironic_username Mar. 25 at 1:13 PM

$ENLV $1.32 to $1.41. This will be nice once it’s warms up a bit more but as I hit my daily target I’m out. Good luck to all the bulls.

0 · Reply

eldemon Mar. 25 at 1:09 PM

$ENLV shorts sound scared

0 · Reply

lowfloatmix Mar. 25 at 1:07 PM

$ENLV wow fake bots going crazy after this scam report. Co. may never recover if they run this scam

1 · Reply

Desertlaw Mar. 25 at 1:05 PM

$ENLV SELL

0 · Reply

Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48

Mar 24, 2026, 8:30 AM EDT - 1 day ago

Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program

Mar 23, 2026, 8:00 AM EDT - 2 days ago

Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

Feb 10, 2026, 8:00 AM EST - 6 weeks ago

Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange

Jan 26, 2026, 8:00 AM EST - 2 months ago

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange

Jan 23, 2026, 8:00 AM EST - 2 months ago

Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq

Jan 14, 2026, 11:46 AM EST - 2 months ago

Analyst Sees Massive Upside For Penny Stock Enlivex After RAIN Token Gains Momentum

Dec 4, 2025, 8:00 AM EST - 3 months ago

Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development

Nov 24, 2025, 10:00 AM EST - 4 months ago

Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors

Nov 24, 2025, 7:55 AM EST - 4 months ago

Enlivex Announces $212,000,000 Private Placement to Initiate World's First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board

Nov 24, 2025, 6:40 AM EST - 4 months ago

Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis

Oct 28, 2025, 8:15 AM EDT - 5 months ago

Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025

Sep 29, 2025, 8:15 AM EDT - 6 months ago

D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program

Sep 11, 2025, 8:00 AM EDT - 6 months ago

Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results

Sep 9, 2025, 8:00 AM EDT - 7 months ago

Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Aug 18, 2025, 7:45 AM EDT - 7 months ago

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

Aug 14, 2025, 8:30 AM EDT - 7 months ago

Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar

Jul 28, 2025, 8:30 AM EDT - 8 months ago

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

Jun 10, 2025, 8:30 AM EDT - 10 months ago

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology

May 20, 2025, 8:00 AM EDT - 11 months ago

Enlivex Selected to Present at Israeli BioMed 2025 Conference

Apr 23, 2025, 8:30 AM EDT - 1 year ago

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress

Apr 21, 2025, 8:30 AM EDT - 1 year ago

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Mar 4, 2025, 4:30 PM EST - 1 year ago

Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis

Mar 3, 2025, 8:22 AM EST - 1 year ago

Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis

Feb 18, 2025, 6:20 AM EST - 1 year ago

Enlivex Issues Urgent Statement on Fraudulent News Dissemination

Jan 10, 2025, 9:00 AM EST - 1 year ago

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIAF

Dec 11, 2024, 8:30 AM EST - 1 year ago

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Dec 5, 2024, 10:49 AM EST - 1 year ago

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Nov 26, 2024, 10:15 AM EST - 1 year ago

Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3

Nov 14, 2024, 8:00 AM EST - 1 year ago

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Oct 30, 2024, 8:00 AM EDT - 1 year ago

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis

Sep 24, 2024, 8:30 AM EDT - 1 year ago

Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Aug 30, 2024, 9:00 AM EDT - 1 year ago

GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jul 19, 2024, 9:00 AM EDT - 1 year ago

Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jun 17, 2024, 8:00 AM EDT - 1 year ago

Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis

May 29, 2024, 4:15 PM EDT - 1 year ago

Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering

May 28, 2024, 8:12 AM EDT - 1 year ago

Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering

Apr 16, 2024, 7:50 AM EDT - 2 years ago

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Apr 11, 2024, 2:58 PM EDT - 2 years ago

Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis

Apr 11, 2024, 8:05 AM EDT - 2 years ago

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis

Mar 22, 2024, 10:50 AM EDT - 2 years ago

Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

UMAC

Feb 26, 2024, 8:30 AM EST - 2 years ago

Enlivex Receives Regulatory Authorization From Israel's Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis

Feb 21, 2024, 8:30 AM EST - 2 years ago

Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals

Jan 17, 2024, 8:00 AM EST - 2 years ago

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

Dec 20, 2023, 8:00 AM EST - 2 years ago

Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis

Jul 31, 2023, 8:00 AM EDT - 2 years ago

Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis

Jun 6, 2023, 8:00 AM EDT - 3 years ago

Enlivex to Present at the 2023 Jefferies Healthcare Conference

May 31, 2023, 8:04 AM EDT - 3 years ago

Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy

Burg44 Mar. 25 at 7:57 PM

$ENLV Crazy, they have $25 per share and only around $1? If this stock was rated as an average stock with a PE of 20x, that makes this $500 per share !!!

0 · Reply

Supera15 Mar. 25 at 5:38 PM

$ENLV didnt know a stock has to be a pos upon good news.

0 · Reply

trt102967 Mar. 25 at 4:31 PM

$ENLV

0 · Reply

PSM_EmpowerTrading Mar. 25 at 1:25 PM

0 · Reply

topstockalerts Mar. 25 at 1:17 PM

$ENLV waking up..

1 · Reply

MadMaverick Mar. 25 at 1:16 PM

0 · Reply

ironic_username Mar. 25 at 1:13 PM

$ENLV $1.32 to $1.41. This will be nice once it’s warms up a bit more but as I hit my daily target I’m out. Good luck to all the bulls.

0 · Reply

eldemon Mar. 25 at 1:09 PM

$ENLV shorts sound scared

0 · Reply

lowfloatmix Mar. 25 at 1:07 PM

$ENLV wow fake bots going crazy after this scam report. Co. may never recover if they run this scam

1 · Reply

Desertlaw Mar. 25 at 1:05 PM

$ENLV SELL

0 · Reply

WheresHunter Mar. 25 at 1:04 PM

$ENLV can we get this to $2

1 · Reply

lowfloatmix Mar. 25 at 1:00 PM

$ENLV if this gets pushed up im shorting tf out of this fake ass report... its clinical stage with no money smh

0 · Reply

lowfloatmix Mar. 25 at 12:58 PM

$ENLV fake news

1 · Reply

TA_Kongen Mar. 25 at 12:47 PM

$ENLV Enlivex (Nasdaq: ENLV) reported 2025 audited results with net income $1.23 billion and diluted EPS $25.48, driven by unrealized appreciation in its treasury and treasury-related derivative assets. The company reported $2.31 billion in treasury assets, $1.93 billion shareholders' equity and $30.0 million in cash and short-term digital investments. Enlivex reiterates a dual strategy combining clinical-stage longevity therapeutics and a prediction-markets-backed treasury model and will host a webcast on March 25, 2026 at 09:00 am ET to discuss results. LOL. Nice accounting practices you fking morons.

0 · Reply

WheresHunter Mar. 25 at 12:46 PM

$ENLV we finally going to blow by 1.25

0 · Reply

WheresHunter Mar. 25 at 12:45 PM

$ENLV this bitch is moving,finally

0 · Reply

Stock_Catcher Mar. 25 at 12:43 PM

$ENLV Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48

0 · Reply

Stock_Catcher Mar. 24 at 12:32 PM

$ENLV Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program

0 · Reply

leahmcdonald Mar. 23 at 8:06 PM

$ENLV 🫡

1 · Reply

leahmcdonald Mar. 23 at 8:04 PM

$ENLV

0 · Reply

StocktwitsNews Mar. 23 at 4:38 PM

Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis $ENLV https://stocktwits.com/news/others/business/quality-longevity-company-enlivex-receives-investigational-new-drug-ind-clearance-from-the-fda-for-phase-2b-trial-of-allocetra-in-age-related-primary-moderate-to-severe-knee-osteoarthritis/cZ3m0wzRI0t

0 · Reply

Stock_Catcher Mar. 23 at 12:05 PM

$ENLV ENLV Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

0 · Reply

Market Cap	239.76M
Revenue (ttm)	0.00
Net Income (ttm)	-15.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	855,299
Avg Vol	487,302
Day's Range	N/A - N/A
Shares Out	237.38M
Stochastic %K	21%
Beta	1.63
Analysts	Sell
Price Target	$13.00